BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 26751493)

  • 1. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tauopathy: A common mechanism for neurodegeneration and brain aging.
    Saha P; Sen N
    Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
    Moore KBE; Hung TJ; Fortin JS
    Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
    Das G; Ghosh S
    ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death.
    Thal DR; Tomé SO
    Brain Res Bull; 2022 Nov; 190():204-217. PubMed ID: 36244581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
    Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
    Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
    Lin LF; Luo HM
    Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau Protein Interaction Partners and Their Roles in Alzheimer's Disease and Other Tauopathies.
    Sinsky J; Pichlerova K; Hanes J
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
    Pradeepkiran JA; Reddy AP; Reddy PH
    Drug Discov Today; 2019 Feb; 24(2):616-623. PubMed ID: 30453058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.